Drug Approval

US FDA Approves Lilly's Mounjaro for Cardiovascular Risk Reduction, Expanding GLP-1 Drug Indications

Core Summary The U.S. Food and Drug Administration (FDA) has approved Eli Lilly’s Mounjaro (tirzepatide) for reducing cardiovascular risk, marking a major expansion of GLP-1 drug indications. Previously used primarily for treating type 2 diabetes and obesity, the drug is now proven to significantly reduce the risk of heart attacks and strokes. This decision places Mounjaro in direct competition with Novo Nordisk’s Ozempic in the cardiovascular protection space, signaling a new phase in metabolic disease treatment. ...

FDA Approves New Pancreatic Cancer Drug, Ending Decades of Treatment Dilemma

Core Summary The U.S. Food and Drug Administration has officially approved an innovative drug for pancreatic cancer treatment, considered the most important therapeutic breakthrough in this field in decades. Pancreatic cancer, known as the “king of cancers” due to its high mortality rate and limited treatment options, now offers new survival hope for tens of thousands of patients with this new drug approval. Event Details According to The Wall Street Journal, this FDA approval marks a major milestone in pancreatic cancer treatment. Pancreatic cancer is the third leading cause of cancer death in the United States, with a five-year survival rate of only about 12%, far lower than most other common cancers. For a long time, treatment options have been largely limited to chemotherapy and surgery, with most patients diagnosed at advanced stages. ...

FDA Commissioner Defends Agency Drug Approval Decisions Amid Industry Criticism

The FDA commissioner publicly defended the agency’s drug approval decisions, responding to criticism from pharmaceutical companies and some lawmakers, emphasizing that approval standards will not be lowered under political pressure.

FDA Expands Access to Promising Pancreatic Cancer Drug daraxonrasib

The FDA has granted expanded access to Revolution Medicines’ targeted pancreatic cancer drug daraxonrasib, opening a pathway for more patients to receive a therapy that has shown promising results in clinical trials.

FDA Grants Early Access to Promising Pancreatic Cancer Drug Daraxonrasib

The FDA approves an expanded access program for daraxonrasib, an innovative pancreatic cancer drug that showed promising results in clinical trials, offering new hope for patients with one of the most challenging cancers.

FDA Plans to Accelerate Clinical Trial Approvals Using AI and Real-Time Data

The US FDA has announced plans to introduce AI and real-time data technology to accelerate drug clinical trial approvals, marking a fundamental shift in drug development regulatory processes.